Pyrazole compound

Patent metadata

Field	Value
Publication number	US-10087146-B2
Application number	US-201715491130-A
Country	US
Kind code	B2
Filing date	Apr 19, 2017
Priority date	Jul 15, 2010
Publication date	Oct 2, 2018
Grant date	Oct 2, 2018

Abstract

The present invention relates to a novel serotonin reuptake inhibitor which also exhibits 5-HT 2C antagonistic action (antidepressive and anxiolytic effects), in particular, 5-HT 2C inverse agonistic action comprising Compound (1):

or a pharmaceutically acceptable salt thereof
wherein R 1 , R 2 , R 3 and R 4 are independently hydrogen or C 1-6 alkyl etc.; R 5 is C 4-7 alkyl or —(CR 8 R 9 ) r -E; R 6 , R 7 , R 8 and R 9 are independently hydrogen, fluorine or C 1-6 alkyl; A is C 6-10 aryl or heteroaryl etc.; r is 1, 2, 3 or 4; E is C 3-8 cycloalkyl or C 6-10 aryl etc.; L is oxygen, sulfur or —NR 10 —; n is 1, 2 or 3; R 10 is hydrogen or C 1-6 alkyl etc.; and X is hydrogen or halogen etc.

First claim

The invention claimed is:

1. A compound of Formula (A-10):

or a salt thereof wherein
R 3 and R 4 are independently selected from the group consisting of hydrogen atom and a C 1-6 alkyl group,
R 5 is an optionally-substituted C 4-7 alkyl group or —(CR 8 R 9 ) r -E,
R 6 , R 7 , R 8 and R 9 are independently selected from the group consisting of hydrogen atom, fluorine atom and an optionally-substituted C 1-6 alkyl group,
A is an optionally-substituted C 6-10 aryl group or an optionally-substituted 5- to 10-membered heteroaryl group,
r is 1, 2, 3 or 4,
E is an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 4-8 cycloalkenyl group, an optionally-substituted 5- to 10-membered saturated heterocyclic group which comprises 1 to 3 heteroatoms independently selected from the group consisting of oxygen atom and sulfur atom as a constituent atom of the ring, an optionally-substituted C 6-10 aryl group or an optionally-substituted 5- to 10-membered heteroaryl group,
n is 1, 2 or 3, and
LG is a leaving group.

2. A compound of Formula (B-9):

or a salt thereof wherein
R 3 and R 4 are independently selected from the group consisting of hydrogen atom and a C 1-6 alkyl group,
R 5 is an optionally-substituted C 4-7 alkyl group or —(CR 8 R 9 ) r -E,
R 6 , R 7 , R 8 and R 9 are independently selected from the group consisting of hydrogen atom, fluorine atom and an optionally-substituted C 1-6 alkyl group,
A is an optionally-substituted C 6-10 aryl group or an optionally-substituted 5- to 10-membered heteroaryl group,
r is 1, 2, 3 or 4,
E is an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 4-8 cycloalkenyl group, an optionally-substituted 5- to 10-membered saturated heterocyclic group which comprises 1 to 3 heteroatoms independently selected from the group consisting of oxygen atom and sulfur atom as a constituent atom of the ring, an optionally-substituted C 6-10 aryl group or an optionally-substituted 5- to 10-membered heteroaryl group, and
n is 1, 2 or 3.

3. A compound of Formula (A-13):

or a salt thereof wherein
R 5 is an optionally-substituted C 4-7 alkyl group or —(CR 8 R 9 ) r -E,
R 6 , R 7 , R 8 and R 9 are independently selected from the group consisting of hydrogen atom, fluorine atom and an optionally-substituted C 1-6 alkyl group,
A is an optionally-substituted C 6-10 aryl group or an optionally-substituted 5- to 10-membered heteroaryl group,
r is 1, 2, 3 or 4,
E is an optionally-substituted C 3-8 cycloalkyl group, an optionally-substituted C 4-8 cycloalkenyl group, an optionally-substituted 5- to 10-membered saturated heterocyclic group which comprises 1 to 3 heteroatoms independently selected from the group consisting of oxygen atom and sulfur atom as a constituent atom of the ring, an optionally-substituted C 6-10 aryl group or an optionally-substituted 5- to 10-membered heteroaryl group,
n is 1, 2 or 3, and
R a is hydrogen atom or a C 1-6 alkyl group.

Assignees

• Sumitomo Dainippon Pharma Co Ltd

Inventors

• Sasaki Izumi
• Toyoda Tomohiro
• Yoshinaga Hidefumi
• Natsutani Itaru
• Takahashi Yoko

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P5/00

  Drugs for disorders of the endocrine system · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P25/30

  for treating abuse or dependence · CPC title